About: Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 02 June 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в червні 2009 (uk) مقالة علمية نشرت في 02 يونيو 2009 (ar) scientific article published on 02 June 2009 (en)
publication date	wds:Q37257725-C7240434-884B-474C-A5B9-A2B316F31046
publication date	2009-06-02 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37257725-D64FA6A2-6392-463C-815E-A450C272D61C
language of work or name	English
cites work	wds:Q37257725-003D3CFA-2C99-45D2-8726-BC1B606023CE wds:Q37257725-0B9C0844-F5E2-4E9F-96E7-ADB0C840C723 wds:Q37257725-0F274F9B-C785-4833-8EB9-93851D430F2B wds:Q37257725-0F8124F3-E2DD-4285-8203-20F2BC23C64C wds:Q37257725-36F319E1-6FD1-43AF-9419-7B0A375FC0E2 wds:Q37257725-3D853C41-688D-4D75-B854-7DCE1881C8F1 wds:Q37257725-43150AAB-65C2-4DA1-BAB3-5472634A6883 wds:Q37257725-4733CA9D-BC2E-4EED-BC2E-297492B9DD73 wds:Q37257725-5E449EBC-E13C-4158-AF18-FBEEF61BF9C4 wds:Q37257725-66E0A802-A6B9-480B-9701-341B1AACF4A1 wds:Q37257725-78F74A15-D8ED-4767-B406-18002E2BD157 wds:Q37257725-801F4DCD-DAC2-44D2-A678-34BAF76B70AD wds:Q37257725-8CCDA919-8AD3-4260-92BE-CEAC3F05A9BF wds:Q37257725-93DA48E7-84FE-476A-B1D3-1256CFEBB0AB wds:Q37257725-A7898188-4723-4ABA-AB25-7C5F2BBEEBF3 wds:Q37257725-ADAD1DDE-290D-4410-AD4D-F2155E9D6EFD wds:Q37257725-C765FF4C-76A7-467E-A040-F43F01D0C987 wds:Q37257725-CB78A7F6-3A65-4707-8189-D14A76C7816D wds:Q37257725-DF4CC320-7A98-49BF-9AD1-4BEC0F0BF251
cites work	Ocular allergy overview Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis Allergic and immunologic disorders of the eye. Part II: ocular allergy Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model Interactions of olopatadine and selected antihistamines with model and natural membranes An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model Drug treatment of allergic conjunctivitis. A review of the evidence Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo A survey of the burden of allergic rhinitis in the USA Histamine receptors and the conjunctiva Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge Evidence-based study design in ocular allergy trials Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge
author name string	wds:Q37257725-33A8935F-6111-41C9-B971-EBDE83B57E2E wds:Q37257725-35C28A3B-BBD0-478F-9F15-DF853C9E0127 wds:Q37257725-8511C215-B4FC-4D86-8C82-38AE931EFE51 wds:Q37257725-87B1D769-D551-49C5-A451-EED31846738E
author name string	Warner W Carr Alan Kaufman Arthur B Epstein Peter T Van Hoven
rdfs:label	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. (nl) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (en) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (ast)
skos:prefLabel	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. (nl) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (en) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (ast)
name	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. (nl) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (en) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (ast)
title	wds:Q37257725-2628389A-E049-4A61-854D-624425863BC5
title	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (en)
page(s)	wds:Q37257725-C0826166-B229-4186-90E0-E5AC36FAFA7F
page(s)	329-336
instance of	wds:Q37257725-57A83B92-A8A4-445C-8C3B-3D3BB149CCAF
instance of	scholarly article
main subject	wds:Q37257725-03B3DBA6-A406-4EBA-9A57-69E44A11CF01 wds:Q37257725-5B348B05-4508-4545-B59D-F9301A2AB98D
main subject	azelastine allergic conjunctivitis
PubMed ID	wds:Q37257725-5366BD71-BCE2-4048-BE4F-3C51D36706FC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19668586
PubMed ID	19668586
published in	wds:Q37257725-F532E779-A576-494A-85FD-462BC2AE409B
published in	Clinical Ophthalmology
volume	wds:Q37257725-CD4506E1-344A-4A46-8315-72DDF0CFE3FE
volume	3
DOI	wds:Q37257725-E0F6AD08-C201-4444-A3FA-76FBDA6D8A4D
DOI	http://dx.doi.org/10.2147/OPTH.S5223
DOI	10.2147/OPTH.S5223
copyright license	wds:Q37257725-9865bf26-2c9f-4459-acfe-9851a9d8c563
copyright status	wds:Q37257725-84276e51-615e-4837-9172-57ef1a56b419
copyright license	Creative Commons Attribution-NonCommercial 3.0 Unported
copyright status	copyrighted

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software